Working with industry
The Maurice Wilkins Centre supports innovation in the biotechnology and drug development sector by providing companies with the expertise and facilities that their research and development programmes require.
Allergan, headquartered in Ireland, is a global pharmaceutical company with a focus on developing new medicines in critical therapeutic areas. Associate Investigator Dr Kerry Loomes from the University of Auckland is working with Allergan to develop new therapeutic strategies to combat metabolic disease.
Auckland Clinical Studies Ltd.
This company provides Phase I and II clinical research to local and international pharmaceutical and biotechnology companies. In 2017 Maurice Wilkins Centre investigators Professor Rod Dunbar, Dr Anna Brooks and Dr Vaughan Feisst continued to work with Auckland Clinical Studies, providing analytical services to support ongoing clinical trials sponsored by a major pharmaceutical company.
Avalia Immunotherapies Ltd.
Avalia Immunotherapies is developing immunotherapies that support the treatment of cancers and other diseases. Investigators Professor Gavin Painter from the Ferrier Research Institute and Associate Professor Ian Hermans from the Malaghan Institute of Medical Research have patented a new cancer immunotherapy technology and will be working with Avalia Immunotherapies to further advance the technology and progress it to clinical trials.
Comvita New Zealand is an international natural health products company with offices across Asia, the USA and UK. Comvita are working with investigators Distinguished Professor Margaret Brimble and Associate Professor Kerry Loomes to identify the active components and biomarkers present in Manuka honey.
This company is based in Auckland and undertakes research, development and manufacture of invasive animal pest control technologies. The company aims to develop smarter pest control products which are humane, cost effective and more specifically targeted to pest species. Maurice Wilkins Centre investigator Distinguished Professor Margaret Brimble is working with the company on designing and synthesizing new molecules as humane rodenticides to replace the toxin 1080.
New Zealand Pharmaceuticals Ltd.
New Zealand Pharmaceuticals Ltd. Manufactures pharmaceutical intermediates and diagnostic products for the pharmaceutical and biotechnology companies. Professors Gary Evans and Richard Furneaux, MWC associate investigators, are working with New Zealand Pharmaceuticals Ltd on bile acid chemistry.
Sapvax LLC was founded in 2016 and is developing a pipeline of products for the treatment of different cancers, with an initial focus on tumours expressing NY-ESO-1. Professors Margaret Brimble and Rod Dunbar are the academic founders of this company, which is headquartered in the USA, and in 2017 they continued to consult and carry out contract research for the company.